Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tepedino, Miguel
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial	Recruiting	N/A	390	US	Active treatment, Sham	Viveve Inc.	Urinary Incontinence, Stress	12/22	12/22
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease	Active, not recruiting	N/A	12000	Europe, US	Low-dose CT scan	Guardant Health, Inc.	Lung Cancer	12/24	12/25
Dyer, Crystal
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease	Active, not recruiting	N/A	12000	Europe, US	Low-dose CT scan	Guardant Health, Inc.	Lung Cancer	12/24	12/25